We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
Read MoreHide Full Article
BioNTech’s (BNTX - Free Report) shares rose almost 4% on Jun 2. This occurred soon after interim data from an ongoing phase I/II study on its anti-CTLA-4 monoclonal antibody, BNT316/ONC-392, demonstrated encouraging signs of clinical anti-tumor activity in a difficult-to-treat lung cancer indication.
The initial data from the study also showed the candidate’s manageable safety profile in patients with metastatic, PD-(L)1-resistant non-small cell lung cancer (NSCLC).
These results will be presented at the annual meeting of the American Society of Clinical Oncology, this week.
The study included 27 patients with metastatic, PD-(L)1-resistant NSCLC who received a minimum of two doses of 10 mg/kg of BNT316/ONC-392. The overall response rate among evaluated patients was 29.6% at data cut-off, with a disease control rate of 70.4%.
BioNTech’s shares have plunged 28% year to date compared with the industry’s 7.6% decline.
Image Source: Zacks Investment Research
Lung cancer is a leading cause of cancer deaths globally, and NSCLC accounts for approximately 85% of all lung cancers. BNT316/ONC-392 is a next-generation anti-CTLA-4 antibody, jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy for various solid tumor indications. The candidate is aimed to block a protein called CTLA-4.
BNT316/ONC-392 is designed to target CTLA-4 for addressing advanced, hard-to-treat tumors. It received Fast Track designation from the FDA in April 2022 for treating patients with metastatic, PD-(L)1-resistant NSCLC.
The abovementioned new data will further support the initiation of a phase III study evaluating BNT316/ONC-392 as monotherapy for immunotherapy-resistant NSCLC. The study, named PRESERVE-003, is planned to commence by the third quarter of 2023.
The candidate will be competing with AstraZeneca's (AZN - Free Report) approved injection Imjudo (tremelimumab) — a CTLA-4 antigen — which is to be administered in combination with AZN’s another cancer drug, Imfinzi (durvalumab). Imjudo was approved for treating patients with advanced liver cancer and lung cancer indication in October and November 2022, respectively.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss per share of $3.46 to loss of $2.78 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 14.7% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss per share of 19 cents to 9 cents for 2023 in the past 90 days. In the year so far, shares of ADMA Biologics have risen 4.4%.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
BioNTech’s (BNTX - Free Report) shares rose almost 4% on Jun 2. This occurred soon after interim data from an ongoing phase I/II study on its anti-CTLA-4 monoclonal antibody, BNT316/ONC-392, demonstrated encouraging signs of clinical anti-tumor activity in a difficult-to-treat lung cancer indication.
The initial data from the study also showed the candidate’s manageable safety profile in patients with metastatic, PD-(L)1-resistant non-small cell lung cancer (NSCLC).
These results will be presented at the annual meeting of the American Society of Clinical Oncology, this week.
The study included 27 patients with metastatic, PD-(L)1-resistant NSCLC who received a minimum of two doses of 10 mg/kg of BNT316/ONC-392. The overall response rate among evaluated patients was 29.6% at data cut-off, with a disease control rate of 70.4%.
BioNTech’s shares have plunged 28% year to date compared with the industry’s 7.6% decline.
Image Source: Zacks Investment Research
Lung cancer is a leading cause of cancer deaths globally, and NSCLC accounts for approximately 85% of all lung cancers. BNT316/ONC-392 is a next-generation anti-CTLA-4 antibody, jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy for various solid tumor indications. The candidate is aimed to block a protein called CTLA-4.
BNT316/ONC-392 is designed to target CTLA-4 for addressing advanced, hard-to-treat tumors. It received Fast Track designation from the FDA in April 2022 for treating patients with metastatic, PD-(L)1-resistant NSCLC.
The abovementioned new data will further support the initiation of a phase III study evaluating BNT316/ONC-392 as monotherapy for immunotherapy-resistant NSCLC. The study, named PRESERVE-003, is planned to commence by the third quarter of 2023.
The candidate will be competing with AstraZeneca's (AZN - Free Report) approved injection Imjudo (tremelimumab) — a CTLA-4 antigen — which is to be administered in combination with AZN’s another cancer drug, Imfinzi (durvalumab). Imjudo was approved for treating patients with advanced liver cancer and lung cancer indication in October and November 2022, respectively.
BioNTech SE Sponsored ADR Price and Consensus
BioNTech SE Sponsored ADR price-consensus-chart | BioNTech SE Sponsored ADR Quote
Zacks Rank and Stocks to Consider
Currently, BioNTech carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) and ADMA Biologics, Inc. (ADMA - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss per share of $3.46 to loss of $2.78 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 14.7% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss per share of 19 cents to 9 cents for 2023 in the past 90 days. In the year so far, shares of ADMA Biologics have risen 4.4%.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.